Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program

Summary:  Genmab and GSK have announced the initiation of the Phase III program 
with ofatumumab to treat rheumatoid arthritis.                                  

Copenhagen, Denmark; November 20, 2007 - Genmab A/S (OMX: GEN) and              
GlaxoSmithKline (LSE and NYSE: GSK) announced today the initiation of the Phase 
III program with ofatumumab to treat rheumatoid arthritis (RA). The program will
commence with two studies (GEN410/OFA110635 and GEN411/OFA110634) which will be 
conducted outside the US, in two distinct patient populations. One study will be
in patients who have had an inadequate response to methotrexate therapy and the 
other in patients who had an inadequate response to TNF-alpha antagonist        
therapy.  Further studies to support the program are planned for 2008.          

Each study will evaluate the efficacy of ofatumumab in reducing the clinical    
signs and symptoms in RA patients after a single course of ofatumumab and are   
comprised of a 24 week double-blind period followed by a 120 week open-label    
period during which re-treatment will be studied. The primary endpoint in each  
study is ACR20 at 24 weeks.                                                     

“This brings us closer to our goal of broadening the treatment options for      
patients with this painful and debilitating disease,” said Lisa N. Drakeman,    
Ph.D., Chief Executive Officer of Genmab. “From the data to date, we believe    
that ofatumumab has real potential.  Now that Phase 3 studies are underway in   
multiple indications, we are moving closer to realizing this potential and      
bringing this important treatment to patients.”                                 
                                                                                
“We are very pleased that our collaboration with Genmab has progressed so that  
we can now move to the next step of the clinical trial program,” said Dr. Moncef
Slaoui, Chairman of Research and Development, GlaxoSmithKline.                  

Ofatumumab is an investigational, fully human, next generation monoclonal       
antibody that targets a unique epitope of the CD20 receptor on the surface of   
B-cells. This epitope is different than other anti-CD20 antibodies currently    
available or in development.                                                    

About the trials                                                                
GEN410/OFA110635 - Clinical efficacy and safety of ofatumumab in adult RA       
patients who had an inadequate response to methotrexate                         
A total of approximately 250 patients who had an inadequate response to         
methotrexate therapy will be enrolled. In the double-blind period, patients will
be randomized to receive two 700 mg doses of ofatumumab or placebo two weeks    
apart in addition to background methotrexate. Rescue treatment with nonbiologic 
disease modifying anti-rheumatic drugs (DMARDs) will be allowed from week 16 in 
the double-blind period.   All patients who complete the double-blind period    
without receiving rescue treatment will continue into the open-label period of  
the study.  Re-treatment will be studied starting at week 24.  Disease status   
will be measured every 4 weeks during the double-blind period and every 8 weeks 
during the open-label period.                                                   

GEN411/OFA110634 - Clinical efficacy and safety of ofatumumab in adult RA       
patients who have had an inadequate response to TNF-alpha antagonist therapy    
A total of approximately 250 patients who had an inadequate response to         
TNF-alpha antagonist therapy will be enrolled. In the double-blind period,      
patients will be randomized to receive two 700 mg doses of ofatumumab or placebo
two weeks apart in addition to background methotrexate.  Rescue treatment with  
nonbiologic disease modifying anti-rheumatic drugs (DMARDs) will be allowed from
week 16 in the double-blind period.  All patients who complete the double-blind 
period without rescue treatment will continue into the open-label period of the 
study. Re-treatment will be studied starting at week 24.  Disease status will be
measured every 4 weeks during the double-blind period and every 8 weeks during  
the open-label period.  
                                                        
About Genmab A/S                                                                
Genmab is a leading international biotechnology company focused on developing   
fully human antibody therapeutics for unmet medical needs.  Using unique,       
cutting-edge antibody technology, Genmab's world class discovery and development
teams have created and developed an extensive pipeline of products for potential
treatment of a variety of diseases including cancer and autoimmune disorders.   
As Genmab advances towards a commercial future, we remain committed to our      
primary goal of improving the lives of patients who are in urgent need of new   
treatment options.  For more information on Genmab's products and technology,   
visit www.genmab.com.                                                           

About GlaxoSmithKline                                                           
GlaxoSmithKline is one of the world's leading research-based pharmaceutical and 
healthcare companies and is committed to improving the quality of human life by 
enabling people to do more, feel better and live longer. For more information,  
visit GlaxoSmithKline on the World Wide Web at www.gsk.com.                     

Genmab forward looking statements                                               
This press release contains forward looking statements. The words “believe”,    
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify    
forward looking statements. Actual results or performance may differ materially 
from any future results or performance expressed or implied by such statements. 
The important factors that could cause our actual results or performance to     
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical   
trials including unforeseen safety issues, uncertainties related to product     
manufacturing, the lack of market acceptance of our products, our inability to  
manage growth, the competitive environment in relation to our business area and 
markets, our inability to attract and retain suitably qualified personnel, the  
unenforceability or lack of protection of our patents and proprietary rights,   
our relationships with affiliated entities, changes and developments in         
technology which may render our products obsolete, and other factors. Genmab is 
not under an obligation to up-date statements regarding the future following the
publication of this release; nor to confirm such statements in relation to      
actual results, unless this is required by law.                                 

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R);  
HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM);   
and UniBody(R) are all trademarks of Genmab A/S.                                

GlaxoSmithKline Forward-Looking Statements                                      
Under the safe harbor provisions of the US Private Securities Litigation Reform 
Act of 1995, the company cautions investors that any forward-looking statements 
or projections made by the company, including those made in this announcement,  
are subject to risks and uncertainties that may cause actual results to differ  
materially from those projected.  Factors that may affect the Group's operations
are described under 'Risk Factors' in the Business and Prospects in the         
company's Annual Report on Form 20-F for 2006.                                  

Contact:		                                                                      
Genmab                                                                          
Helle Husted, Sr. Director, Investor Relations                                  
T: +45 33 44 77 30; M: +45 25 27 47 13; E: hth@genmab.com                       

GlaxoSmithKline                                                                 
UK Media                                                                        
Claire Brough                                                                   
T: +44 20 8047 5505                                                             

US Media                                                                        
Nancy Pekarek                                                                   
T: +1 919 483 2839                                                              

                                                                                
Stock Exchange Release no. 53/2007                                              

###